Free drugs can help prevent repeat heart attacks
This Nov. 15, 2005 file photo shows 40 milligram tablets of Lipitor, one kind of statin used for lowering blood cholesterol, in Glen Rock, N.J. A study led by a Boston researcher and presented Monday, Nov. 14, 2011 finds that offering people free medicines after a heart attack can help cut the chances they will suffer another one. It also saves them about $500 for health care over the next year without raising costs for insurers. However, doctors were shocked that only about half of these patients filled their prescriptions even though they got them free. (AP Photo/Mel Evans, File)
Give people free prescription drugs and many of them still won't bother to take their medicine.
Doctors were stunned to see that happen in a major study involving heart attack survivors. The patients were offered well-established drugs to prevent a recurrence of heart trouble, including cholesterol-lowering statins and medicines that slow the heart and help it pump more effectively.
"My God, we gave these people the medicines for free and only half took it," said one of the study's authors, Dr. Elliott Antman of Harvard-affiliated Brigham and Women's Hospital in Boston.
In fact, the researchers couldn't even give the stuff away: They had trouble just signing up patients to take part in the study.
Nevertheless, Aetna, the insurance company that footed the bill, thinks this approach will save money in the long run and plans to start offering certain heart drugs free to some patients. In the study, patients offered medicines at no cost suffered fewer heart problems and saved $500 on average over roughly a year.
It is no secret many Americans don't follow their doctors' instructions. In one survey, one-third said they didn't fill a prescription or used less medicine than they should because of cost. The researchers in this study wanted to see what would happen if they took cost out of the equation.
The results were disheartening.
"Adherence in America is miserable," lamented Dr. Eric Peterson of Duke University, who had no role in the study. He noted that only 10 percent of the patients were taking all the medicines they should one year after a heart attack.
The study was led by Dr. Niteesh Choudhry of Brigham and Women's, who presented the findings Monday at an American Heart Association conference in Florida. They also were published online by The New England Journal of Medicine.
The study did not examine why people didn't take their medications. But doctors know that some forget. Most of these drugs mean three pills a day or more, for the rest of a patient's life. Also, some of these medicines carry side effects such as fatigue, lightheadedness, muscle pains, cough, even sexual difficulties for men.
Still, heart attack survivors like Joan Ferraro, 53, of Freehold, N.J., said they can't imagine not taking prescribed medicines, though she sometimes forgets her pills over a weekend.
"Why would you want to go through something like that again? It was the most horrific experience of my life. I would never want another one," she said.
The study enrolled 5,855 Aetna members who had a drug plan as part of their benefits and were going home from the hospital after a heart attack. They were 53 years old on average, and three-fourths were men.
The researchers had hoped to recruit 7,500 patients but scaled back when so few signed on.
Preventive medicines were offered free to 2,845 patients and prescribed with the usual copayments for the rest. Copays for these drugs run around $50 a month.
Roughly a year later, the share of patients who filled their prescriptions ranged from 36 percent to 49 percent in the no-copay group, depending on the drug, and was only 4 to 6 percentage points higher in the group that had no copays.
Providing these medicines for free had a "distressingly modest" effect on patients' willingness to take them, Dr. Lee Goldman of Columbia University and Dr. Arnold Epstein of the Harvard School of Public Health wrote in an editorial in the medical journal.
The Commonwealth Fund, a foundation devoted to improving the health care system, helped pay for the study, and some of authors consult for insurance companies.
In the study, the total number of heart attacks, strokes, cases of chest pain or heart failure and other such problems was significantly lower in the group offered free medicine.
That meant that an additional 2 of every 100 people were spared such problems because they were offered free medicines. Doctors suspect the difference between the groups would have been greater if more people had actually filled their prescriptions.
Costs dropped 26 percent for patients in the free drug group compared with the others, partly because of fewer doctor visits, lab tests and hospitalizations.
The costs for the insurer averaged $69,997 over a year for those with the usual coverage and $64,726 for those offered free medicines. That was not considered a significant difference statistically, but insurers looking at the bottom line would still view it as worthwhile.
Dr. Lonny Reisman, an author of the study and chief medical officer for Aetna, said the company plans to offer some of these drugs free or with a reduced copay to some heart attack survivors and is considering doing do so for other chronic conditions such as diabetes and chronic lung disease.
The study may persuade other insurers to do the same, Goldman and Epstein said.
Heart Association: http://www.americanheart.org
New England Journal: http://www.nejm.org
©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Eliminating co-payments for heart attack medications increases adherence Nov 14, 2011 | not rated yet | 0
- Study: New drug cuts deaths after heart attack Nov 13, 2011 | not rated yet | 0
- Barrier to effective treatment for seniors -- the cost of medicine Aug 01, 2011 | not rated yet | 0
- Cost of heart drugs makes patients skip pills, putting themselves at risk Mar 29, 2011 | not rated yet | 0
- Doctor-pharmacist partnership reduces hospitalization for heart failure Aug 18, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
18 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications 4 hours ago | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications 5 hours ago | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications May 22, 2013 | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications May 22, 2013 | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
4 hours ago | 4.8 / 5 (5) | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
8 hours ago | 5 / 5 (1) | 2 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
8 hours ago | 5 / 5 (2) | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
10 hours ago | 4.9 / 5 (7) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
8 hours ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
6 hours ago | not rated yet | 0 |